Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TNBC - Triple-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01031446
What this trial is testing

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 55
Large-scale testing (Phase 3)Temporarily pausedNCT03777579
What this trial is testing

First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Who this might be right for
Triple Negative Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 375
Post-approval studies (Phase 4)Looking for participantsNCT04790305
What this trial is testing

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Who this might be right for
Carcinoma BreastTriple-negative Breast CancerInvasive Ductal Carcinoma, Breast
Fudan University 1,072
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT01815242
What this trial is testing

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 336
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07139470
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 59
Early research (Phase 1)Study completedNCT01674842
What this trial is testing

Cisplatin + RT for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 55
Testing effectiveness (Phase 2)Study completedNCT06685796
What this trial is testing

BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast Cancer
BeBetter Med Inc 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT04734262
What this trial is testing

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Metastatic Breast Cancer
Fudan University 98
Testing effectiveness (Phase 2)Study completedNCT00691379
What this trial is testing

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Not applicableActive Not RecruitingNCT06833723
What this trial is testing

Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes

Who this might be right for
Breast Neoplasms
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences 1,000
Early research (Phase 1)Study completedNCT01238952
What this trial is testing

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 4
Testing effectiveness (Phase 2)Study completedNCT02187991
What this trial is testing

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumors+1 more
US Oncology Research 169
Not applicableLooking for participantsNCT07046455
What this trial is testing

Trop-2 Targeted PET Probes in Advanced TNBC

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Peking University Cancer Hospital & Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT05219578
What this trial is testing

RTX-224 Monotherapy in Patients With Solid Tumors

Who this might be right for
Non Small Cell Lung CancerCutaneous MelanomaHead and Neck Squamous Cell Carcinoma+2 more
Rubius Therapeutics 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06407310
What this trial is testing

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Tel Aviv Medical Center 25
Not applicableLooking for participantsNCT06582615
What this trial is testing

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Ohio State University Comprehensive Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT03435640
What this trial is testing

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Who this might be right for
MelanomaMerkel Cell CarcinomaTriple Negative Breast Cancer+4 more
Nektar Therapeutics 64
Not applicableStudy completedNCT04368468
What this trial is testing

Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC

Who this might be right for
Triple Negative Breast Cancer
Institut Claudius Regaud 100
Next Page